Labeled metronidazoles as potential new agents for amebic hepatic abscess imaging.
Two new radiopharmaceuticals were developed as possible agents for demonstrating the presence of hepatic amebic abscesses by selective accumulation of these agents in the abscess contents. These agents are: 131I-labeled Bromometronidazole, that has been shown to possess some of the antibiotic activity of metronidazole or Flagyl; and a Technetium 99m-penicillamine-Flagyl complex. A method of radioiodination has been devised which can be performed in radiopharmaceutical laboratories. Both radiopharmaceuticals are of very low toxicity. Distribution studies in animals show accumulation in the liver and elimination by way of the gallbladder. Scintillation camera studies depict a rapid uptake by the liver with subsequent biliary excretion. Animal models for the study of hepatic amebic abscesses are not available. A human patient with suspected amebic abscesses has been studied with negative findings that were confirmed at surgery. Collaborative studies are now in progress in several areas of the world where amebiases is endemic.
D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D003937:Diagnosis, Differential; D004285:Dogs; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008101:Liver Abscess, Amebic / Q000175:diagnosis*; D008107:Liver Diseases / Q000175:diagnosis; D008297:Male; D008795:Metronidazole / Q000378:metabolism / Q000633:toxicity; D051379:Mice; D010396:Penicillamine; D011817:Rabbits; D011877:Radionuclide Imaging; D051381:Rats; D013667:Technetium
D007457:Iodine Radioisotopes; D008795:Metronidazole; D013667:Technetium; D010396:Penicillamine